Successful treatment of disseminated granuloma annulare with adalimumab

J Drugs Dermatol. 2009 Feb;8(2):169-71.


A 61-year-old female with a 4-year history of disseminated granuloma annulare was successfully treated with the antitumor necrosis factor (TNF)-alpha antibody, adalimumab. The patient had failed high potency topical glucocorticoids, hydroxychloroquine, and narrow-band ultraviolet light (UV)-B phototherapy. Anti-TNF-alpha therapy may be a therapeutic option in patients with disseminated granuloma annulare poorly controlled with conventional medications.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Biopsy
  • Female
  • Granuloma Annulare / drug therapy*
  • Granuloma Annulare / immunology
  • Granuloma Annulare / pathology
  • Histiocytes / pathology
  • Histiocytes / ultrastructure
  • Humans
  • Middle Aged
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors


  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Adalimumab